Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: Calaspargase PegolProcedure: Computed TomographyDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: DexamethasoneDrug: DoxorubicinProcedure: EchocardiographyProcedure: Lumbar PunctureDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanBiological: NavitoclaxDrug: PegaspargaseDrug: NelarabineProcedure: Positron Emission TomographyDrug: ThioguanineProcedure: X-Ray ImagingDrug: VenetoclaxDrug: Vincristine
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT06210750
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
- Conditions
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 33
- Registration Number
- NCT06207123
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
BV-AVD-R Treatment Children Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Beijing Children's Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06201507
- Locations
- 🇨🇳
Duan Yanlong, Beijing, China
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 1080
- Registration Number
- NCT06191744
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States
🇺🇸Christiana Care Health Service /ID# 261207, Newark, Delaware, United States
🇺🇸Oncology Hematology Care, Inc - Blue Ash /ID# 261204, Cincinnati, Ohio, United States
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
- Conditions
- Interventions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 150
- Registration Number
- NCT06175702
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CarboplatinDrug: CisplatinProcedure: Computed TomographyDrug: CyclophosphamideBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Hematopoietic Cell TransplantationDrug: IrinotecanDrug: IsotretinoinProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingDrug: MelphalanRadiation: Radiation TherapyProcedure: Radionuclide ImagingOther: Survey AdministrationDrug: TemozolomideDrug: ThiotepaDrug: TopotecanProcedure: Tumor ResectionDrug: Vincristine
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 478
- Registration Number
- NCT06172296
- Locations
- 🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyBiological: BlinatumomabDrug: Calaspargase PegolDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: DaunorubicinDrug: DoxorubicinProcedure: EchocardiographyDrug: LeucovorinDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PegaspargaseDrug: PrednisoloneDrug: PrednisoneDrug: VincristineRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 680
- Registration Number
- NCT06124157
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 733
- Registration Number
- NCT06097364
- Locations
- 🇨🇱
Hospital Clinico Universidad de Los Andes, Santiago, Las Condes, Chile
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 904
- Registration Number
- NCT06091865
- Locations
- 🇫🇷
Hopital Saint Vincent-de-Paul, Lille, Nord, France
🇰🇷St. Vincent Hospital - The Catholic University of Korea, Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Yeouido St. Marys Hospital, Seoul, Korea, Republic of
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 478
- Registration Number
- NCT06091254
- Locations
- 🇪🇸
Hospital Clinico Universitario Valencia, Valencia, Spain
🇪🇸Hospital Universitary and Politecnic La Fe, Valencia, Spain
🇨🇭Kantonsspital Baden, Baden, Aargau, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.